{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:28Z","timestamp":1792177708387,"version":"4.4.0"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Summary of recommendations<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n\n<jats:list-item><jats:p>Pregnant women should be managed by a multidisciplinary team that includes haematologists, obstetricians, neonatologists and anaesthetists (Grade 1C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>As for non\u2010pregnant patients, acute myeloid leukaemia (AML) should be diagnosed using the World Health Organization (WHO) classification (Grade 1A)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Women diagnosed with AML in pregnancy should be treated without delay (Grade 1B)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>When the diagnosis of AML is made in the first trimester, a successful pregnancy outcome is unlikely and spontaneous pregnancy loss in this situation carries considerable risks for the mother. The reasons for and against elective termination should be discussed with the patient (Grade 2C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>In the case of presentation beyond 32\u00a0weeks gestation, it may be reasonable to deliver the foetus prior to commencement of chemotherapy (Grade 2C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Between 24 and 32\u00a0weeks, risks of foetal chemotherapy exposure must be balanced against risks of prematurity following elective delivery at that stage of gestation (Grade 1C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>The risk\u2010benefit ratio must be carefully considered before using any drugs in pregnancy (Grade 1C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Where AML induction chemotherapy is delivered, a standard daunorubicin, cytarabine 3\u00a0+\u00a010 schedule should be used (Grade 1B)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Chemotherapy should be dosed according to actual body weight and adjustments made for weight changes during treatment (Grade 1C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Quinolones, tetracyclines and sulphonamide use should be avoided in pregnancy (Grade 1B)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Amphotericin B or lipid derivatives are the antifungal of choice in pregnancy (Grade 2C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Cytomegalovirus (CMV)\u2010negative blood products should be administered during pregnancy regardless of CMV serostatus (Grade 1B)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>A course of corticosteroids should be considered if delivery is anticipated between 24 and 35\u00a0weeks gestation, given over a 48\u2010h period during the week prior to delivery (Grade 1A)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Use of magnesium sulphate should be considered in the 24\u00a0h prior to delivery if this is before 30\u00a0weeks gestation (Grade 1A)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Where possible, delivery should be planned for a time when the woman is at least 3\u00a0weeks post\u2010chemotherapy to minimize risk of neonatal myelosuppression (Grade 1C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Planned delivery is easier to manage than spontaneous labour; induction of labour is usually advised (Grade 2C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Epidural analgesia should be avoided in a woman who is significantly thrombocytopenic (platelet count &lt;80\u00a0\u00d7\u00a010<jats:sup>9<\/jats:sup>\/l) and\/or neutropenic (white blood cell count &lt;1\u00a0\u00d7\u00a010<jats:sup>9<\/jats:sup>\/l): (Grade 1C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Elective caesarean section should only be recommended for obstetric indications (Grade 2C)<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Antibiotics should be administered during and after premature rupture of membranes and delivery (Grade 1C)<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p>","DOI":"10.1111\/bjh.13554","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T08:40:52Z","timestamp":1434530452000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy"],"prefix":"10.1111","volume":"170","author":[{"given":"Sahra","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Haematology Hull Royal Infirmary Hull and East Yorkshire Hospitals NHS Trust Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail L.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Haematology Freeman Hospital Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Culligan","sequence":"additional","affiliation":[{"name":"Department of Haematology Aberdeen Royal Infirmary Aberdeen UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa J.","family":"Marsden","sequence":"additional","affiliation":[{"name":"Department of Women's Services Royal Victoria Infirmary Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Haematology Nottingham City Hospital Nottingham University Hospitals NHS Trust Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Embleton","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Royal Victoria Infirmary Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[{"name":"Department of Haematology University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the British Committee for Standards in Haematology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01957002"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950160102"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198408000-00032"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(04)01466-4"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21137"},{"key":"e_1_2_16_7_1","unstructured":"Department of Health. (2012)SaBTO (Advisory Committee on the safety of Blood Tissues and Organs) Cytomegalovirus Tested Blood Components Position Statement.UK Department of Health. [Date accessed 1 June 2014].https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/215125\/dh_133086.pdf"},{"key":"e_1_2_16_8_1","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/archinte.1988.00380090118027","article-title":"Management of cancer during pregnancy","volume":"148","author":"Doll D.C.","year":"1988","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(97)82004-9"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2004.00236.x"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109060347"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2005.08.008"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/514977"},{"key":"e_1_2_16_14_1","first-page":"1365","article-title":"Use of antibiotics during pregnancy","volume":"43","author":"Lynch C.M.","year":"1991","journal-title":"American Family Physician"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0705.2001.00373.x"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12091"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.7.1098"},{"key":"e_1_2_16_18_1","volume-title":"Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium","author":"Royal College of Obstetricians and Gynaecologists","year":"2009"},{"key":"e_1_2_16_19_1","volume-title":"Antenatal Corticosteroids to Reduce Neonatal Morbidity and Mortality","author":"Royal College of Obstetricians and Gynaecologists","year":"2010"},{"key":"e_1_2_16_20_1","volume-title":"Magnesium Sulphate to Prevent Cerebral Palsy","author":"Royal College of Obstetricians and Gynaecologists","year":"2011"},{"key":"e_1_2_16_21_1","volume-title":"Bacterial Sepsis in Pregnancy","author":"Royal College of Obstetricians and Gynaecologists","year":"2012"},{"key":"e_1_2_16_22_1","volume-title":"Bacterial Sepsis Following Pregnancy","author":"Royal College of Obstetricians and Gynaecologists","year":"2012"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150250"},{"key":"e_1_2_16_24_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archinte.1981.00340040110026","article-title":"Teratogenic effects of antileukemic chemotherapy","volume":"141","author":"Schafer A.I.","year":"1981","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2008.03.006"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880201)61:3<435::AID-CNCR2820610305>3.0.CO;2-F"},{"key":"e_1_2_16_27_1","volume-title":"Treatment of Nausea and Vomiting in Pregnancy","author":"UKTIS","year":"2010"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2801"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92986-4"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.4.5.889"},{"key":"e_1_2_16_32_1","first-page":"57","article-title":"Is this drug going to harm my baby?","volume":"48","author":"Yaffe S.","year":"2003","journal-title":"Contemporary Obstetrics & Gynecology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13554","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:14:10Z","timestamp":1696349650000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/bjh.13554"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13554","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]},"assertion":[{"value":"2015-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}